GlycoMimetics Inc - ESG Rating & Company Profile powered by AI
Complete Sustainability assessment of GlycoMimetics Inc are accessed by signing in. Alternative companies in the rating industry group for GlycoMimetics Inc are displayed below. The page contains a free Sustainability assessment for GlycoMimetics Inc.
GlycoMimetics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.2; made up of an environmental score of 0.0, social score of 1.6 and governance score of 2.0.
1.2
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1755 | TRACON Pharmaceuticals Inc | 1.3 | Low |
| 1755 | Trimurthi Ltd | 1.3 | Low |
| 1779 | GlycoMimetics Inc | 1.2 | Low |
| 1779 | Cell Biotech Co Ltd | 1.2 | Low |
| 1779 | Aurisco Pharmaceutical Co Ltd | 1.2 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does GlycoMimetics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes GlycoMimetics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes GlycoMimetics Inc report the average age of the workforce?
Sign up for free to unlockDoes GlycoMimetics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes GlycoMimetics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes GlycoMimetics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes GlycoMimetics Inc offer flexible work?
Sign up for free to unlockDoes GlycoMimetics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes GlycoMimetics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes GlycoMimetics Inc conduct supply chain audits?
Sign up for free to unlockDoes GlycoMimetics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes GlycoMimetics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes GlycoMimetics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes GlycoMimetics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes GlycoMimetics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes GlycoMimetics Inc disclose water use targets?
Sign up for free to unlockDoes GlycoMimetics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid GlycoMimetics Inc have a product recall in the last two years?
Sign up for free to unlockDoes GlycoMimetics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes GlycoMimetics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas GlycoMimetics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes GlycoMimetics Inc disclose parental leave metrics?
Sign up for free to unlockDoes GlycoMimetics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes GlycoMimetics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes GlycoMimetics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes GlycoMimetics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes GlycoMimetics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes GlycoMimetics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs GlycoMimetics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes GlycoMimetics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes GlycoMimetics Inc disclose its waste policy?
Sign up for free to unlockDoes GlycoMimetics Inc report according to TCFD requirements?
Sign up for free to unlockDoes GlycoMimetics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes GlycoMimetics Inc disclose energy use targets?
Sign up for free to unlockDoes GlycoMimetics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes GlycoMimetics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for GlycoMimetics Inc
These potential risks are based on the size, segment and geographies of the company.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.